Completed PHASE2 INTERVENTIONAL NCT00002943

Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer

High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Bone Marrow Transplantation for Relapsed and Refractory Germ Cell Cancer: A Phase II Pilot Study

Sponsor: National Cancer Institute (NCI)

Conditions Extragonadal Germ Cell Tumor Ovarian Cancer Testicular Germ Cell Tumor Unspecified Adult Solid Tumor, Protocol Specific

Interventions autologous bone marrow transplantation carboplatin cyclophosphamide etoposide

Updated 6 times since 2017 Last updated: Aug 8, 2018 Started: Feb 28, 1993 Primary completion: Oct 31, 2003 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Extragonadal Germ Cell Tumor and Ovarian Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 1993 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Sep 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Wake Forest University Health Sciences

Data source: Wake Forest University Health Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Winston-Salem, United States